Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of AstraZeneca's Puxitatug Samrotecan?
Puxitatug Samrotecan is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Phase II program in Solid Tumor;Peritoneal Cancer....
Data Insights
Risk adjusted net present value: What is the current valuation of AstraZeneca's Puxitatug Samrotecan?
Puxitatug Samrotecan is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Phase II program in Metastatic Bile Duct...